Sarepta Therapeutics said it is quitting enrollment for the confirmatory Phase 3 trial of Elevidys (delandistrogene moxeparvovec-rokl). The source indicates the move is intended to follow a course change after expectations for confirmatory evidence in older boys. The decision is likely to reshape Elevidys confirmatory strategy, timelines, and regulatory planning for Duchenne muscular dystrophy programs built around the gene-therapy platform. Companies and investors will now focus on what data package Sarepta will use to satisfy confirmatory requirements. Clinicians will also monitor implications for patient access and the design of any future studies intended to confirm benefit and safety in broader subgroups.